FIELD: medicine; cardiology.
SUBSTANCE: invention can be used to predict the probability of adverse cardiovascular events in patients with coronary heart disease who have undergone planned coronary myocardial revascularization. In patients, the concentrations of omentin-1, lipocalin associated with neutrophil gelatinase, apelin, and growth differentiation factor-15 are determined in the blood serum. Body mass index is calculated. Then the probability of adverse cardiovascular events (P) is calculated using the original formula. With a P value of 0.5 or more, a high probability of adverse cardiovascular events is predicted.
EFFECT: method makes it possible to predict the probability of adverse cardiovascular events in patients with coronary heart disease who have undergone planned coronary myocardial revascularization, which increases the accuracy of diagnosis and influences treatment tactics, and makes it possible to obtain an individual risk profile for a particular patient.
1 cl, 1 dwg, 2 ex
